Neoplasms

All Conditions

Nervous System Diseases

Gland and Hormone Related Diseases

Rare Diseases

Adenoma

Pituitary Diseases

Pituitary Neoplasms

ACTH-Secreting Pituitary Adenoma

Hypothalamic Diseases

Brain Diseases

Central Nervous System Diseases

Endocrine System Diseases

Endocrine Gland Neoplasms

Hypothalamic Neoplasms

Supratentorial Neoplasms

Brain Neoplasms

Central Nervous System Neoplasms

Nervous System Neoplasms

ACTH-secreting Pituitary Adenoma

All Drugs and Chemicals

Somatostatin

Pasireotide

Adrenocorticotropic Hormone

Hormones

Hormone Antagonists

Subjects will receive Pasireotide LAR monthly. Safety labs and Pituitary MRI will be performed.

Pasireotide LAR (SIGNIFOR® LAR) is a somatostatin analog indicated for the treatment of patients with acromegaly who have had an inadequate response to surgery and/or for whom surgery is not an option. It is a long acting release injectable suspension for intramuscular use.

The starting dose is Pasireotide LAR 40 mg/month intramuscular (IM), this will be increased to 60 mg/month at 6 months if a fall in POMC levels and/or tumor shrinkage are not attained.

Pasireotide LAR

Pamela Freda, MD

This is a phase II, open-label, 12-month pilot study in 10 patients with silent corticotroph pituitary tumors testing the hypotheses that Pasireotide long-acting release (LAR) treatment of patients with silent corticotroph pituitary tumors and elevated plasma Proopiomelanocortin (POMC) levels will reduce plasma POMC levels and this will be associated with a reduction in pituitary tumor size. Pasireotide LAR 40 mg will be administered monthly. Baseline and monthly visits on therapy will monitor plasma levels of POMC, other pituitary function, safety labs, glucose tolerance, physical examination, and visual fields. Pituitary magnetic resonance imaging (MRI) will be done at baseline, 6 months and 12 months of therapy. The eligible patient population will consist of adult patients with known silent corticotroph pituitary tumors and elevated plasma levels of POMC.

Clinically non-functioning pituitary adenomas (CNFAs), the subtype of pituitary adenomas that does not appear to secrete biologically active hormone nor to have a characteristic clinical phenotype, are the most common type of pituitary macroadenoma at diagnosis. There is currently no option for medical therapy of CNFA, in general, or specifically of silent corticotroph tumors. Silent corticotroph tumors can range from being completely asymptomatic to becoming large and causing significant hypothalamic/pituitary dysfunction and visual symptoms, and most data support that this type of tumor has a more aggressive phenotype. Current therapy consists primarily of surgical removal of the tumor and for recurrent or residual tumors, repeated surgery and/or radiotherapy. In very aggressive tumors, chemotherapy has been tried with some success. Therefore, a need exists for a medical therapeutic option for the treatment of this tumor type. This project assesses this clinical need.

Pasireotide LAR Therapy of Silent Corticotroph Pituitary Tumors

Pilot Study of Pasireotide LAR Treatment of Silent Corticotrophin Pituitary Tumors and Effects on Plasma Levels of POMC

This is to measure the effect of Pasireotide LAR (long-acting release) treatment.

Columbia University

Professor of Medicine at the Columbia University Medical Center, Dept of Medicine Endocrinology

Subjects will receive Pasireotide LAR monthly. Safety labs and Pituitary MRI will be performed.

Pasireotide LAR: Pasireotide LAR (SIGNIFOR® LAR) is a somatostatin analog indicated for the treatment of patients with acromegaly who have had an inadequate response to surgery and/or for whom surgery is not an option. It is a long acting release injectable suspension for intramuscular use.

The starting dose is Pasireotide LAR 40 mg/month intramuscular (IM), this will be increased to 60 mg/month at 6 months if a fall in POMC levels and/or tumor shrinkage are not attained.

Pasireotide LAR Therapy

Age, Categorical

Sex: Female, Male

Race (NIH/OMB)

United States

Region of Enrollment

The study was terminated due to poor enrollment.

Pamela U. Freda, MD

The study was terminated due to poor enrollment. The data was not collected or analyzed.

Change in Plasma Proopiomelanocortin (POMC) Levels

Change in Pituitary Tumor Volume

Overall Study

Spots Global Cancer Trial Database for silent corticotroph adenomas